![Myeloma Crowd Radio: Irene Ghobrial, MD & Salomon Manier, MD, PhD, Dana Farber 09/27 by HealthTree Podcast for MM | Health Myeloma Crowd Radio: Irene Ghobrial, MD & Salomon Manier, MD, PhD, Dana Farber 09/27 by HealthTree Podcast for MM | Health](https://dasg7xwmldix6.cloudfront.net/episodes/539173_pt0lg8V3.jpg)
Myeloma Crowd Radio: Irene Ghobrial, MD & Salomon Manier, MD, PhD, Dana Farber 09/27 by HealthTree Podcast for MM | Health
![Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT | Bone Marrow Transplantation Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT | Bone Marrow Transplantation](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41409-023-02048-7/MediaObjects/41409_2023_2048_Fig1_HTML.png)
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT | Bone Marrow Transplantation
![Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results | Nature Medicine Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results | Nature Medicine](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-023-02528-9/MediaObjects/41591_2023_2528_Fig1_HTML.png)
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results | Nature Medicine
![IACH on X: "Join us TODAY at 2pm Eastern Time (Atlanta), 8pm CET (Paris) for live news from #ASH21 with Dr. Salomon Manier and @Mohty_EBMT Register Free here: https://t.co/bdQmP2b0TS https://t.co/oYQD70BBZf" / X IACH on X: "Join us TODAY at 2pm Eastern Time (Atlanta), 8pm CET (Paris) for live news from #ASH21 with Dr. Salomon Manier and @Mohty_EBMT Register Free here: https://t.co/bdQmP2b0TS https://t.co/oYQD70BBZf" / X](https://pbs.twimg.com/media/FGeOEmnXIAMcmn9.jpg)
IACH on X: "Join us TODAY at 2pm Eastern Time (Atlanta), 8pm CET (Paris) for live news from #ASH21 with Dr. Salomon Manier and @Mohty_EBMT Register Free here: https://t.co/bdQmP2b0TS https://t.co/oYQD70BBZf" / X
![Myeloma Crowd Radio: Irene Ghobrial, MD & Salomon Manier, MD, PhD, Dana Farber 09/27 by HealthTree Podcast for MM | Health Myeloma Crowd Radio: Irene Ghobrial, MD & Salomon Manier, MD, PhD, Dana Farber 09/27 by HealthTree Podcast for MM | Health](https://dasg7xwmldix6.cloudfront.net/episodes/539173_RETPcwhp.jpg)
Myeloma Crowd Radio: Irene Ghobrial, MD & Salomon Manier, MD, PhD, Dana Farber 09/27 by HealthTree Podcast for MM | Health
![Multiple Myeloma Hub on X: "#EHA2023 | Salomon Manier @CHU_Lille shares efficacy and safety data on BCMA targeted drugs: CAR T, bispecifics and antibody-drug conjugates. Future directions of CAR T cells include Multiple Myeloma Hub on X: "#EHA2023 | Salomon Manier @CHU_Lille shares efficacy and safety data on BCMA targeted drugs: CAR T, bispecifics and antibody-drug conjugates. Future directions of CAR T cells include](https://pbs.twimg.com/media/FyQI1OvXsAIKsMy.jpg:large)
Multiple Myeloma Hub on X: "#EHA2023 | Salomon Manier @CHU_Lille shares efficacy and safety data on BCMA targeted drugs: CAR T, bispecifics and antibody-drug conjugates. Future directions of CAR T cells include
![Determining the optimal sequencing of bispecifics and CAR-T cells in patients with myeloma - YouTube Determining the optimal sequencing of bispecifics and CAR-T cells in patients with myeloma - YouTube](https://i.ytimg.com/vi/3ZEkBXoAJFw/mqdefault.jpg)